Shp099

Manufactured by MedChemExpress

Sourced in United States

SHP099 is a laboratory equipment product manufactured by MedChemExpress. It is a small molecule that functions as a selective inhibitor.

Automatically generated - may contain errors

Lab products found in correlation

Erk1 2, by Cell Signaling Technology (2 mentions) Microplate reader, by Thermo Fisher Scientific (2 mentions) Syk inhibitor r406, by Selleck Chemicals (1 mentions) Cal 101 idelalisib, by Selleck Chemicals (1 mentions) Fc block reagent, by Miltenyi Biotec (1 mentions) Pnu 74654, by MedChemExpress (1 mentions) Cck 8, by Dojindo Laboratories (1 mentions) Lorlatinib, by Selleck Chemicals (1 mentions) Crizotinib, by Selleck Chemicals (1 mentions) Ceritinib, by Selleck Chemicals (1 mentions) Tno155, by MedChemExpress (1 mentions) Lorlatinib, by MedChemExpress (1 mentions) Originpro 2018, by OriginLab (1 mentions) Recombinant human egf af 100 15, by Thermo Fisher Scientific (1 mentions) Nsc95397, by MedChemExpress (1 mentions) Trametinib, by ChemScene (1 mentions) Kras g12d, by Cell Signaling Technology (1 mentions) Phospho erk1 2 thr202 tyr204 4370, by Cell Signaling Technology (1 mentions) Steap3, by Proteintech (1 mentions) Gapdh, by Cell Signaling Technology (1 mentions)

13 protocols using shp099

Targeting Intracellular Signaling Cascades

Check if the same lab product or an alternative is used in the 5 most similar protocols

Syk inhibitor (R406; 3 µM) and PI3Kδ inhibitor (Idelalisib CAL-101; 3 µM) were from Selleckchem. SHP-1 inhibitor (TPI-1; 3 µM) and SHP-2 inhibitor (SHP099; 10 µM) were from MedChem Express. Fc-block reagent was purchased from Miltenyi Biotech.

Chen Y.C., Burgess M., Mapp S., Mollee P., Gill D., Blumenthal A, & Saunders N.A. (2021). SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients. Frontiers in Immunology, 11, 610523.

+ Open protocol

+ Expand

Viability of Pre-adipocytes Exposed to Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols

The viability of pre-adipocytes was assessed using CCK-8 (Dojindo Laboratories, Inc.) assays according to the manufacturer's instructions following treatment with recombinant leptin rat (0, 5, 25, 50, 100 and 200 ng/ml) (Bioworld Technology, Inc.), SHP099 (0, 1, 5, 10, 50, 100 and 200 µM) or PNU-74654 (0, 0.5, 1, 10, 25, 50 and 100 µM) (MedChemExpress) at 37˚C with 5% CO₂ for 24 h. The absorbance at 450-nm wavelength was detected using a microplate reader (Thermo Fisher Scientific, Inc.).

Qi X., Sun Z., Li X., Jiao Y., Chen S., Song P., Qian Z., Qian J., Qiu X, & Tang L. (2022). Shp2 suppresses fat accumulation in white adipose tissue by activating Wnt/β-catenin signaling following vertical sleeve gastrectomy in obese rats with type-2 diabetes. Experimental and Therapeutic Medicine, 23(4), 302.

+ Open protocol

+ Expand

Murine Tumor Model Drug Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

TNO155 (#HY-136173) and SHP099 (#HY-100388A) were purchased from MedChemExpress, and ceritinib (#S7083), lorlatinib (#S7536), and crizotinib (#S1068) were purchased from Selleck Chemicals. Inhibitors were resuspended in DMSO. For murine experiments, lorlatinib (#HY-12215) and TNO155 (#HY-136173) were purchased from MedChemExpress or TNO155 was provided by Novartis AG. Drugs were resuspended in final concentrations of 0.5% methylcellulose + 0.5% Tween 80 in water.

Valencia-Sama I., Kee L., Christopher G., Ohh M., Layeghifard M., Shlien A., Hayes M.N, & Irwin M.S. (2023). SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma. Cancer Research Communications, 3(12), 2608-2622.

+ Open protocol

+ Expand

Bile Duct Ligation and CCl4-Induced Liver Fibrosis

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Six-week old wild-type (WT) C57Bl/6 male and female mice (Envigo) underwent bile duct ligation (BDL) to induce liver fibrosis, as previously described (21 (link)) and kept 3 weeks. In a second model of liver fibrosis, CCl₄ (1µL/g, Sigma-Aldrich #319961) was administered twice a week for 4 weeks. SHP099 (MedChemExpress, HY-100388) was dissolved in 5%DMSO and administered daily at 5mg/kg for 4weeks. For EV transplant, unlabeled or PKH76-labeled PDGFRα-overexpressing LX2-derived EVs were used; 2×10⁹ EVs/mouse/day (22 (link)) were administered daily for 3–4 weeks. Serum and livers were analyzed by Sirius red, Masson’s trichrome and WB. Serum EVs derived from olive oil-, CCl₄- or CCl₄+SHP099-treated mice were administrated daily at 100µg of EVs/mouse/day to WT mice for 10 days. CCl₄, SHP099 and EVs were administered intraperitoneally.

Kostallari E., Hirsova P., Prasnicka A., Verma V.K., Yaqoob U., Wongjarupong N., Roberts L.R, & Shah V.H. (2018). Hepatic stellate cell-derived PDGFRα-enriched extracellular vesicles promote liver fibrosis in mice through SHP2. Hepatology (Baltimore, Md.), 68(1), 333-348.

+ Open protocol

+ Expand

Phosphatase Inhibition Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Phosphatase activity was measured in the presence of various concentrations of the inhibitor SHP099 (MedChemExpress) in activity buffer containing 500 μM DiFMUP in absence and presence of 5 μM synthetic, biphosphorylated IRS-1 peptide (H₂N-LN(pY)IDLDLV(dPEG8)LST(pY)ASINFQK-amide, Anaspec). Percentage of inhibition was plotted against the logarithmic concentration of SHP099 and the IC₅₀ values and uncertainties were obtained after fitting the data to the Boltzmann function in OriginPro 2018 (OriginLab, Northampton, MA).

Pádua R.A., Sun Y., Marko I., Pitsawong W., Stiller J.B., Otten R, & Kern D. (2018). Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nature Communications, 9, 4507.

+ Open protocol

+ Expand

Molecular Probes for Cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Raphin1 acetate (HY-123960A), Sanguinarine chloride (HY-N0052A), KY-226 (HY-120327), SHP099 (HY-100388), NSC95397 (HY-108543), and BCI (HY-115502) were purchased from MedChemExpress. BIRB796 (Axon 1358) was purchased from Axon Medchem. Recombinant human EGF (AF-100-15) was purchased from Peprotech.

Eguchi A, & Olsen J.V. (2024). Phosphoproteomic investigation of targets of protein phosphatases in EGFR signaling. Scientific Reports, 14, 7908.

+ Open protocol

+ Expand

Inhibition of Oncogenic Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Trametinib (MEK inhibitor) was obtained from ChemScene, SHP099 (SHP-2 inhibitor) from MedChem Express, and calpeptin (cell-penetrating calpain inhibitor) from Calbiochem.

Harigai R., Sato R., Hirose C., Takenouchi T., Kosaki K., Hirose T., Saya H, & Arima Y. (2022). Mutation of PTPN11 (Encoding SHP-2) Promotes MEK Activation and Malignant Progression in Neurofibromin-Deficient Cells in a Manner Sensitive to BRAP Mutation. Cancers, 14(10), 2377.

+ Open protocol

+ Expand

KRAS Signaling Pathway Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used: KRAS G12D (14429; dilution: 1:1,000; Cell Signaling Technology); KRAS (53270; dilution: 1:1,000; Cell Signaling Technology); phospho-Erk1/2 (Thr202/Tyr204; 4370; dilution: 1:1,000; Cell Signaling Technology); Erk1/2 (4696; dilution: 1:1,000; Cell Signaling Technology); GAPDH (5,174; dilution: 1:1,000; Cell Signaling Technology); STEAP3 (17186; dilution: 1:1,000; Proteintech); and ferroportin (NBP1-21502SS; dilution: 1:1,000; Novus Biologicals). COBI and SHP099 were purchased from MedChemExpress. RMC-4550 material used in these studies was provided by Revolution Medicines, Inc., in collaboration with Sanofi, Paris, France.

Jiang H., Muir R.K., Gonciarz R.L., Olshen A.B., Yeh I., Hann B.C., Zhao N., Wang Y.H., Behr S.C., Korkola J.E., Evans M.J., Collisson E.A, & Renslo A.R. (2022). Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. The Journal of Experimental Medicine, 219(4), e20210739.

+ Open protocol

+ Expand

Comprehensive Profiling of Receptor Tyrosine Kinase Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies EGFR (#4267), p-EGFR (#3777), ERBB2 (#2242), p-ERBB2 (#2243), ERBB3 (#4754), p-ERBB3 (#4791), ERK1/2 (#4696), p-ERK1/2 (T202/Y204, #9101), AKT (#9272) and p-AKT (#6942) were purchased from Cell Signaling Technology. β-tubulin antibody (#sc-166729) was purchased from Santa Cruz Biotech and actin antibody (#A2066) from Sigma-Aldrich. Afatinib was purchased from Selleck Chemicals LLC; erlotinib, selumetinib and SHP099 from MedChem Express; and trametinib from ChemieTek. Therapeutic antibodies trastuzumab and pertuzumab were obtained from Roche, Finland.

Murumägi A., Ungureanu D., Khan S., Arjama M., Välimäki K., Ianevski A., Ianevski P., Bergström R., Dini A., Kanerva A., Koivisto-Korander R., Tapper J., Lassus H., Loukovaara M., Mägi A., Hirasawa A., Aoki D., Pietiäinen V., Pellinen T., Bützow R., Aittokallio T, & Kallioniemi O. (2022). Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. British Journal of Cancer, 128(4), 678-690.

+ Open protocol

+ Expand

Investigating Innate Immune Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

SHP099 (Cat. #HY-100388) and SHP099 hydrochloride (Cat. #HY-100388A) were purchased from MedChemExpress (Monmouth Junction, NJ, USA). 2′,3′-cGAMP (Cat. #tlrl-nacga23) was purchased from InvivoGen (San Diego, CA, USA). ELISA Kits for human and mouse IFN-β were purchased from Multi Sciences Biotech Co., Ltd. (Hangzhou, China). Anti-p-TBK1 (Cat. #5483) and anti-p-IRF3 (Cat. #4947) were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-TBK1 (Cat. #DF7026) was purchased from Affinity Biosciences (Cincinnati, OH, USA). Anti-IRF3 (Cat. #11312-1-AP) and anti-STING (Cat. #19851-1-AP) were purchased from Proteintech Group (Rosemont, IL, USA). Anti-SHP2 (Cat. #sc-7384) was purchased from were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-β-actin (Cat. #M20011) was purchased from Abmart (Shanghai, China). Alexa Fluor 488 goat anti-rabbit IgG (H + L) cross-adsorbed secondary antibody (Cat. #A11008) was purchased from ThermoFisher Scientific (Waltham, MA, USA). All other chemicals were obtained from Sigma–Aldrich (St. Louis, MO, USA).

Gao J., Wu Z., Zhao M., Zhang R., Li M., Sun D., Cheng H., Qi X., Shen Y., Xu Q., Chen H., Chen D, & Sun Y. (2021). Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics. Acta Pharmaceutica Sinica. B, 12(1), 149-166.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!